keyword
MENU ▼
Read by QxMD icon Read
search

DC-CIK

keyword
https://www.readbyqxmd.com/read/29348890/adoptive-immunotherapy-shows-encouraging-benefit-on-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#1
Binghao Zhao, Wenxiong Zhang, Dongliang Yu, Jianjun Xu, Yiping Wei
Although adoptive immunotherapy (AIT) is a novel emerging target treatment for non-small cell lung cancer (NSCLC), its actual efficacy remains controversial. In this meta-analysis, we aimed to evaluate the efficacy of AIT for NSCLC. We systematically searched PubMed, the Cochrane Library, EMBASE, Medline, and Web of Science for relevant parallel randomized controlled trials (RCTs) and high-quality observation studies of AIT without any language restrictions. Two investigators reviewed all the texts and extracted information regarding overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), and disease control rate (DCR) from eligible studies; sensitivity analyses and subgroup analyses were also conducted to reduce heterogeneity Of 319 suitable studies, 15 studies (13 RCTs and 2 observation studies) involving 1684 patients were finally included...
December 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29247502/immunotherapy-excluding-checkpoint-inhibitors-for-stage-i-to-iii-non-small-cell-lung-cancer-treated-with-surgery-or-radiotherapy-with-curative-intent
#2
REVIEW
Jianwei Zhu, Rui Li, Eva Tiselius, Raheleh Roudi, Olivia Teghararian, Chen Suo, Huan Song
BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common lung cancer, accounting for approximately 80% to 85% of all cases. For patients with localised NSCLC (stages I to III), it has been speculated that immunotherapy may be helpful for reducing postoperative recurrence rates, or improving the clinical outcomes of current treatment for unresectable tumours. While several new agents have now entered phase III clinical trials, we felt a systematic review was needed to address the question of the effectiveness and safety of immunotherapy in patients with stages I to III NSCLC...
December 16, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29181186/enhanced-antitumor-effects-and-improved-immune-status-of-dendritic-cell-and-cytokine-induced-killer-cell-infusion-in-advanced-cancer-patients
#3
Feng Chen, Menghan Yang, Qingkun Song, Jiangping Wu, Xiaoli Wang, Xinna Zhou, Yanhua Yuan, Yuguang Song, Ni Jiang, Yanjie Zhao, Lei Zhou, Jun Ren
Little progress has been made in the treatment of advanced cancer. Dendritic cells (DCs) plus cytokine-induced killer (CIK) cells have exhibited antitumor effects. Thus, the aim of the present study was to evaluate the clinical efficacy of DC-CIK cell treatment in patients with advanced cancer. A paired study including 57 patients treated with DC-CIK cells (DC-CIK group) and 33 patients treated with best supportive care alone (BSC group) was performed. The patients in the DC-CIK group were matched to those in the control group in terms of sex, age, tumor type and clinical stage...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29180849/adjuvant-immunotherapy-of-dendritic-cells-and-cytokine-induced-killer-cells-is-safe-and-enhances-chemotherapy-efficacy-for-multiple-myeloma-in-china-a-meta-analysis-of-clinical-trials
#4
Yan Wang, Benji Lv, Ke Li, Anqi Zhang, Hong Liu
Objective: The aim of this study was to systematically evaluate the efficacy and safety of the combination of dendritic cells and cytokine-induced killer cells (DC-CIK) adjuvant immunotherapy and chemotherapy in the treatment of multiple myeloma (MM). Methods: Clinical trials were gathered by searching Web of Science, PubMed, Embase, Cochrane Library, Wanfang, and CNKI database. Outcome measurements including therapeutic efficacy, prognosis, immune function, and adverse events were extracted and evaluated...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29179719/effect-of-dendritic-cell-cytokine-induced-killer-cells-in-patients-with-advanced-colorectal-cancer-combined-with-first-line-treatment
#5
Yunqing Xie, Lijie Huang, Luchuan Chen, Xiaowei Lin, Li Chen, Qiuhong Zheng
BACKGROUND: Surgical resection combined with adjuvant chemotherapy is considered as the gold-standard treatment for advanced colorectal cancer patients. These patients have a poor 5-year survival rate of 5% or less. Furthermore, a large dose of chemotherapy can produce adverse side effects and severe toxicity. Therefore, this retrospective study aimed to evaluate the efficacy of dendritic cell-cytokine-induced killer (DC-CIK) cell infusion as an adjuvant therapy in patients with advanced colorectal cancer combined with first-line treatment...
November 28, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29049237/effect-and-safety-of-cytokine-induced-killer-cik-cell-immunotherapy-in-patients-with-breast-cancer-a-meta-analysis
#6
Jianxin Hu, Junfeng Hu, Xiandong Liu, Chao Hu, Ming Li, Wei Han
BACKGROUND: Breast cancer (BC) is considered a systemic disease with a primarily locoregional component. The accumulation of basic researches and clinical studies related to cytokine-induced killer (CIK) cells has confirmed their safety and feasibility in treating BC. By searching the PubMed, Embase, CNKI, and Wanfang databases, we conducted a meta-analysis to assess the efficacy and safety of DC/CIK plus chemotherapy regimen (Exp) compared with chemotherapy (Con) alone regimen for breast carcinoma...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28941416/increased-cycles-of-dc-cik-immunotherapy-decreases-frequency-of-tregs-in-patients-with-resected-nsclc
#7
Haiping Song, Shujuan Liu, Ziyun Zhao, Weihong Sun, Xiaofang Wei, Xuezhen Ma, Peng Zhao, Daiqing Gao
Regulatory T cells (Tregs) suppress antitumor immune responses. Cycles of Dendritic cells (DC) vaccination combined with cytokine-induced killer (CIK) cells (DC/CIK) treatment were significantly related with good prognosis. Therefore, we investigated whether increased cycles of immunotherapy could decrease frequency of Tregs in patients with resected non-small cell lung cancer (NSCLC). Previous study from our laboratory has determined that the optimal cutoff point of the cycle count was 3cycles. We examined the levels of Tregs and the related cytokines by flow cytometric and cytokine analysis in these patients after more than (≥) 3cycles or less than (<) 3cycles of DC/CIK cell treatment...
September 20, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/28860827/clinical-applications-of-dendritic-cells-cytokine-induced-killer-cells-mediated-immunotherapy-for-pancreatic-cancer-an-up-to-date-meta-analysis
#8
Yucai Zhang, Xiaorui Zhang, Anqi Zhang, Ke Li, Kai Qu
PURPOSE: This study aimed to systematically evaluate the efficacy and safety of dendritic cells-cytokine-induced killer (DC-CIK) cells immunotherapy in treating pancreatic cancer (PC) patients. METHODS: Data were collected from published articles of clinical trials. Databases including Web of Science, EMBASE, PubMed, Cochrane Library, Wanfang, and CNKI were searched. The main outcome measures in this research included the overall response rate (ORR), disease control rate (DCR), overall survival (OS), patients' quality of life (QoL), immune function, and adverse events...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28743835/adoptive-immunotherapy-shows-encouraging-benefit-on-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#9
Binghao Zhao, Wenxiong Zhang, Dongliang Yu, Jianjun Xu, Yiping Wei
Although adoptive immunotherapy (AIT) is a novel emerging target treatment for non-small cell lung cancer (NSCLC), its actual efficacy remains controversial. In this meta-analysis, we aimed to evaluate the efficacy of AIT for NSCLC. We systematically searched PubMed, the Cochrane Library, EMBASE, Medline, and Web of Science for relevant parallel randomized controlled trials (RCTs) and high-quality observation studies of AIT without any language restrictions. Two investigators reviewed all the texts and extracted information regarding overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), and disease control rate (DCR) from eligible studies; sensitivity analyses and subgroup analyses were also conducted to reduce heterogeneityOf 319 suitable studies, 15 studies (13 RCTs and 2 observation studies) involving 1684 patients were finally included...
July 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28671084/in-vivo-anti-tumor-effect-of-dc-cik-cells-on-human-lymphoma-cell-line-raji
#10
Xiaolu Zhang, Meihong Du, Quan Zhang, Hongyue Chen, Lin Zhao, Hongjie Li, Weisheng Guo
To research on the effect of DC-CIK cells on human lymphoma cell line Raji the immunophenotype of DC-CIK cells was analyzed using flow cytometry, and its proliferation inhibition effect was detected using MTT assay. 24 nude mice (4-6 weeks old) were employed and inoculated Raji cells on right axillaries for constructing human Burkitt lymphoma model. MTT results showed that DC-CIK cells had a significant inhibitory effect on Raji cells with obvious dose- and time- dependent effect. Western Blot results confirmed that DC-CIK cells could significantly down regulate the expression of BCL-2 (P<0...
May 2017: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28611200/dendritic-cell-cytokine-induced-killer-cell-immunotherapy-combined-with-s-1-in-patients-with-advanced-pancreatic-cancer-a-prospective-study
#11
Ni Jiang, Guoliang Qiao, Xiaoli Wang, Michael A Morse, William R Gwin, Lei Zhou, Yuguang Song, Yanjie Zhao, Feng Chen, Xinna Zhou, Lefu Huang, Amy Hobeika, Xin Yi, Xuefeng Xia, Yanfang Guan, Jin Song, Jun Ren, H Kim Lyerly
Purpose: Advanced pancreatic cancer has remained challenging to treat effectively. This study aimed to investigate the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells (DC-CIK) administered with the chemotherapy (CT) S-1 in this malignancy.Experimental Design: Consecutive patients (n = 47) with advanced pancreatic cancer were treated with either DC-CIK + S-1, DC-CIK alone, S-1 alone, or best supportive care.Results: DC-CIK plus S-1 produced significantly longer median OS and PFS (212 and 136 days) compared with DC-CIK (128 and 85 days), CT (141 and 92 days), or supportive care only (52 and 43 days; P < 0...
June 13, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28572734/folfox-regimen-plus-dendritic-cells-cytokine-induced-killer-cells-immunotherapy-for-the-treatment-of-colorectal-cancer-a-meta-analysis
#12
Yan Liu, Zhong Zheng, Qixin Zhang, Xinling Zhou, Yikuan Feng, Anquan Yan
PURPOSE: To systematically investigate the efficacy and safety of the combination of FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin) regimen and cocultured dendritic cells and cytokine-induced killer cells (DC-CIK) immunotherapy for the treatment of colorectal cancer (CRC). METHODS: Publications reporting the clinical trials' responses or safety of FOLFOX regimen combined with DC-CIK immunotherapy in treating CRC patients were searched in PubMed, Embase, Cochrane Library, China National Knowledge Internet, and Wanfang databases...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28537906/killing-effects-of-huaier-granule-combined-with-dc-cik-on-nude-mice-transplanted-with-colon-carcinoma-cell-line
#13
Wen-Wen Sun, Jin-Xia Dou, Lin Zhang, Li-Kui Qiao, Na Shen, Qiang Zhao, Wen-Yuan Gao
This study aims to compare the efficacy of different treatments for nude mice transplanted with HT-29 colon carcinoma cell line. BalB/C nude mice were transplanted with HT-29 colon carcinoma cell line and randomly divided into four groups, with 5 mice in each group: blank control group, DC-CIK group, Huaier Granule group, and Huaier Granule group combined with DC-CIK group (combined treatment group). For DC-CIK group and combined treatment group, 1×106 DC-CIK cells were injected via the tail vein 4 days after transplantation...
July 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28507788/adaptive-t-cell-responses-induced-by-oncolytic-herpes-simplex-virus-granulocyte-macrophage-colony-stimulating-factor-therapy-expanded-by-dendritic-cell-and-cytokine-induced-killer-cell-adoptive-therapy
#14
Jun Ren, William R Gwin, Xinna Zhou, Xiaoli Wang, Hongyan Huang, Ni Jiang, Lei Zhou, Pankaj Agarwal, Amy Hobeika, Erika Crosby, Zachary C Hartman, Michael A Morse, Kevin H Eng, H Kim Lyerly
Purpose: Although local oncolytic viral therapy (OVT) may enhance tumor lysis, antigen release, and adaptive immune responses, systemic antitumor responses post-therapy are limited. Adoptive immunotherapy with autologous dendritic cells (DC) and cytokine-induced killer cells (DC-CIK) synergizes with systemic therapies. We hypothesized that OVT with Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor (HSV-GM-CSF) would induce adaptive T cell responses that could be expanded systemically with sequential DC-CIK therapy...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28408841/cytokine-induced-killer-cells-dendritic-cells-and-cytokine-induced-killer-cells-immunotherapy-for-the-treatment-of-esophageal-cancer-in-china-a-meta-analysis
#15
Yan Liu, Ying Mu, Anqi Zhang, Shaoda Ren, Weihua Wang, Jiaping Xie, Yingxin Zhang, Changhui Zhou
BACKGROUND: Immunotherapy based on cytokine-induced killer cells or combination of dendritic cells and cytokine-induced killer cells (CIK/DC-CIK) showed promising clinical outcomes for treating esophageal cancer (EC). However, the clinical benefit varies among previous studies. Therefore, it is necessary to systematically evaluate the curative efficacy and safety of CIK/DC-CIK immunotherapy as an adjuvant therapy for conventional therapeutic strategies in the treatment of EC. MATERIALS AND METHODS: Clinical trials published before October 2016 and reporting CIK/DC-CIK immunotherapy treatment responses or safety for EC were searched in Cochrane Library, EMBASE, PubMed, Wanfang and China National Knowledge Internet databases...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28404886/cytokine-induced-killer-cells-dendritic-cells-cytokine-induced-killer-cells-immunotherapy-combined-with-chemotherapy-for-treatment-of-colorectal-cancer-in-china-a-meta-analysis-of-29-trials-involving-2-610-patients
#16
Lei Zhang, Ying Mu, Anqi Zhang, Jiaping Xie, Shuangfeng Chen, Fang Xu, Weihua Wang, Yingxin Zhang, Shaoda Ren, Changhui Zhou
PURPOSE: To systematically evaluate the efficacy and safety of Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells (CIK/DC-CIK) immunotherapy in treating advanced colorectal cancer (CRC) patients. RESULTS: 29 trials including 2,610 CRC patients were evolved. Compared with chemotherapy alone, the combination of chemotherapy with CIK/DC-CIK immunotherapy significantly prolonged the overall survival rate (OS) and disease-free survival rate (DFS) (1-5 year OS, P < 0...
July 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28337381/hla-e-inhibitor-enhances-the-killing-of-neuroblastoma-stem-cells-by-co-cultured-dendritic-cells-and-cytokine-induced-killer-cells-loaded-with-membrane-based-microparticles
#17
Zijun Zhen, Kaibin Yang, Litong Ye, Zhiyao You, Rirong Chen, Ying Liu, Youjian He
Neuroblastoma stem cells (NSCs) can cause drug resistance and tumor recurrence. This study aimed to enhance the lytic effect of dendritic cells (DCs) co-cultured with cytokine-induced killer (CIK) cells. NSCs were obtained by suspension culture, and DC-CIK cells were loaded with extracted NSC membrane-based microparticles (MMPs) before evaluating the lytic effect of DC-CIK cells on NSCs. After inhibiting the function or expression of human leukocyte antigen-E (HLA-E) in NSCs by anti-HLA-E monoclonal antibody or siRNA, the DC-CIK cell lytic effect on NSCs was re-assessed...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28260039/comparative-investigation-of-the-effects-of-specific-antigen%C3%A2-sensitized-dc%C3%A2-cik-and-dc%C3%A2-ctl-cells-against-b16-melanoma-tumor-cells
#18
COMPARATIVE STUDY
Peng-Tao Ren, Yuan Zhang
The use of personalized adoptive immunotherapy as a potential novel approach is promising in the treatment of tumors resistant to conventional therapies. In the present study, dendritic cell (DC)‑cytokine‑induced killer (CIK) and DC‑cytotoxic lymphocyte (CTL) cells were cultured to examine their phenotype, proliferation and cytotoxicity against B16 melanoma tumor cells. In addition, comparative investigations of the effect of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells were performed in vitro and in vivo...
April 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/28143792/2003-2013-a-valuable-study-autologous-tumor-lysate-pulsed-dendritic-cell-immunotherapy-with-cytokine-induced-killer-cells-improves-survival-in-stage-iv-breast-cancer
#19
Mao Lin, Shuzhen Liang, Feng Jiang, Jiongyuan Xu, Weibing Zhu, Wei Qian, Yong Hu, Zhanchun Zhou, Jibing Chen, Lizhi Niu, Kecheng Xu, Youyong Lv
Dendritic cells (DCs) and cytokine-induced killer (CIK) cells have both shown activity as immunotherapy in some malignancies. Our aim was to prospective assess the effect of this immunotherapy in patients with stage IV breast cancer. Between Aug 2003 and Dec 2013, we collected 368 patients who met inclusion criteria and divided into immunotherapy group (treatment group: 188 patients) and chemotherapy group (control group: 180 patients). DCs were prepared from the mononuclear cells isolated from patients in the treatment group using IL-2/GM-CSF and were loaded with tumour antigens; CIK cells were prepared by incubating peripheral blood lymphocytes with IL-2, IFN-γ, and CD3 antibodies...
March 2017: Immunology Letters
https://www.readbyqxmd.com/read/28105230/dendritic-cell-activated-cytokine-induced-killer-cell-mediated-immunotherapy-is-safe-and-effective-for-cancer-patients-65-years-old
#20
Yanfeng Liu, Haibo Liu, Hausheng Liu, Pengcheng He, Jing Li, Xin Liu, Limei Chen, Mengchang Wang, Jiejing Xi, Huaiyu Wang, Haitao Zhang, Ying Zhu, Wei Zhu, Jing Ning, Caili Guo, Chunhong Sun, Mei Zhang
Individuals >65 years old account for a large proportion of cancer patients, and usually have poor prognoses due to relative weaker physiological function and lower drug tolerance. To characterize the efficacy and safety of dendritic cell (DC)-activated cytokine-induced killer cell (CIK)-mediated treatment, and develop an adoptive immunotherapy for cancer patients >65 years old, a retrospective study was performed in 58 cancer sufferers who received 1-4 cycles of DC-activated CIK (DC-CIK) treatment and evaluated the response (tumor remission rate) and toxicity (side effects to the treatment)...
December 2016: Oncology Letters
keyword
keyword
86789
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"